Veru (NASDAQ:VERU) Cut to Sell at Wall Street Zen

Veru (NASDAQ:VERU) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other equities research analysts have also issued reports on VERU. Oppenheimer reiterated an “outperform” rating on shares of Veru in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Veru in a research report on Wednesday, January 21st. Finally, Canaccord Genuity Group assumed coverage on Veru in a report on Thursday, December 18th. They set a “buy” rating and a $25.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Veru Stock Performance

VERU opened at $2.53 on Friday. The firm’s fifty day moving average is $2.43 and its two-hundred day moving average is $3.31. The firm has a market cap of $40.61 million, a PE ratio of -1.15 and a beta of -1.42. Veru has a twelve month low of $2.10 and a twelve month high of $7.40.

Veru (NASDAQ:VERU) last released its quarterly earnings results on Wednesday, December 17th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.18. During the same quarter last year, the firm posted ($0.28) earnings per share. Equities analysts forecast that Veru will post -0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Veru

A number of large investors have recently added to or reduced their stakes in VERU. PVG Asset Management Corp raised its stake in Veru by 3.2% in the 2nd quarter. PVG Asset Management Corp now owns 1,647,365 shares of the company’s stock worth $958,000 after purchasing an additional 50,465 shares in the last quarter. 180 Wealth Advisors LLC increased its holdings in shares of Veru by 5.9% during the second quarter. 180 Wealth Advisors LLC now owns 458,887 shares of the company’s stock worth $267,000 after purchasing an additional 25,554 shares during the period. Blair William & Co. IL raised its position in shares of Veru by 8.6% in the second quarter. Blair William & Co. IL now owns 380,000 shares of the company’s stock valued at $221,000 after buying an additional 30,000 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Veru in the second quarter valued at approximately $220,000. Finally, Sheets Smith Investment Management boosted its stake in shares of Veru by 1,341.9% in the third quarter. Sheets Smith Investment Management now owns 322,084 shares of the company’s stock valued at $1,224,000 after buying an additional 299,746 shares during the period. Institutional investors own 47.16% of the company’s stock.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.